Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium, quantity: 20.7 mg - tablet, enteric coated - excipient ingredients: iron oxide red; glyceryl monostearate; crospovidone; hyprolose; hypromellose phthalate; sucrose; purified talc; macrogol 400; light magnesium oxide; microcrystalline cellulose; lactose monohydrate; maize starch; silicon dioxide; macrogol 6000; pregelatinised maize starch; polysorbate 80; povidone; methacrylic acid copolymer; titanium dioxide; hypromellose; iron oxide yellow - symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium, quantity: 20.7 mg - tablet, enteric coated - excipient ingredients: macrogol 400; silicon dioxide; iron oxide red; hyprolose; methacrylic acid copolymer; purified talc; microcrystalline cellulose; pregelatinised maize starch; sucrose; polysorbate 80; light magnesium oxide; crospovidone; hypromellose phthalate; lactose monohydrate; glyceryl monostearate; macrogol 6000; povidone; maize starch; titanium dioxide; hypromellose; iron oxide yellow - symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium, quantity: 20.7 mg - tablet, enteric coated - excipient ingredients: glyceryl monostearate; polysorbate 80; sucrose; lactose monohydrate; microcrystalline cellulose; macrogol 400; pregelatinised maize starch; povidone; macrogol 6000; hypromellose phthalate; light magnesium oxide; silicon dioxide; purified talc; iron oxide red; maize starch; hyprolose; crospovidone; methacrylic acid copolymer; titanium dioxide; hypromellose; iron oxide yellow - symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; glyceryl monostearate; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; macrogol 6000; pregelatinised maize starch; iron oxide red; maize starch; light magnesium oxide; povidone; sucrose; hyprolose; hypromellose phthalate; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; hypromellose phthalate; glyceryl monostearate; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; macrogol 6000; pregelatinised maize starch; iron oxide red; maize starch; light magnesium oxide; povidone; sucrose; hyprolose; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: crospovidone; hypromellose phthalate; polysorbate 80; purified talc; hyprolose; macrogol 6000; povidone; sucrose; silicon dioxide; maize starch; glyceryl monostearate; iron oxide red; pregelatinised maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; light magnesium oxide; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hyprolose; sucrose; iron oxide red; glyceryl monostearate; polysorbate 80; povidone; light magnesium oxide; purified talc; crospovidone; pregelatinised maize starch; macrogol 400; hypromellose phthalate; maize starch; silicon dioxide; macrogol 6000; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for:,? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: povidone; iron oxide red; crospovidone; hypromellose phthalate; hyprolose; macrogol 400; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; microcrystalline cellulose; macrogol 6000; pregelatinised maize starch; glyceryl monostearate; polysorbate 80; light magnesium oxide; silicon dioxide; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: purified talc; silicon dioxide; microcrystalline cellulose; povidone; pregelatinised maize starch; macrogol 6000; hyprolose; crospovidone; iron oxide red; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; hypromellose phthalate; macrogol 400; polysorbate 80; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - jubium is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; silicon dioxide; iron oxide red; purified talc; hyprolose; macrogol 400; pregelatinised maize starch; macrogol 6000; light magnesium oxide; polysorbate 80; hypromellose phthalate; povidone; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - jubeso is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer